OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma

November 25th 2015

Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, compares the efficacy of dabrafenib plus trametinib versus vemurafenib plus cobimetinib.

Dr. Koo on Degarelix for the Treatment of Prostate Cancer

November 24th 2015

Alec S. Koo, MD, FACS, managing partner, Skyline Urology, board of directors, Large Urology Group Practice Association, discusses degarelix (Firmagon) for the treatment of patients with prostate cancer.

Dr. Hudis on Neoadjuvant Treatment of HER2-Positive Breast Cancer

November 23rd 2015

Clifford A. Hudis, MD, FACP, chief, Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, professor of medicine, Weill Cornell Medical College, takes a deeper look at neoadjuvant treatment for patients with HER2-positive breast cancer.

Dr. Jennifer Brown on Duvelisib in CLL

November 23rd 2015

Jennifer R. Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses duvelisib for the treatment of chronic lymphocytic leukemia (CLL).

Dr. Sundar Jagannath on Significant Studies in Multiple Myeloma

November 18th 2015

Sundar Jagannath, MD, Professor Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the significance of several recent studies in multiple myeloma.

Dr. Leonard on Treatment Options for Patients With Indolent B-Cell NHL

November 16th 2015

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses therapies available for patients with indolent B-cell Non-Hodgkin lymphoma.

Dr. Michael Morris on Combining and Sequencing Radium-223

November 13th 2015

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Dr. Figlin on Sunitinib for Patients With RCC

November 9th 2015

Robert Figlin, MD, FACP, professor of Medicine and Biomedical Sciences, Steven Spielberg Family Chair in Hematology Oncology, director, Division of Hematology Oncology, deputy director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, discusses newer methods of administering sunitinib (Sutent) to patients with renal cell carcinoma.

Dr. Howard L. Kaufman on Impact of T-VEC FDA Approval

November 6th 2015

Howard L. Kaufman, MD, FACS, Chief Surgical Officer, Associate Director for Clinical Science, Surgical Oncologist, Rutgers Cancer Institute, Society for Immunotherapy of Cancer (SITC) President, discusses the impact of the recent FDA approval of talimogene laherparepvec (T-VEC) for the treatment of melanoma lesions in the skin and lymph nodes.

Willem Overwijk Explains the Role of the Innate Immune System in Cancer Treatment

November 6th 2015

Willem Overwijk, PhD, Associate Professor, Department of Melanoma Medical Oncology, Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, explains the role of innate immunity in the treatment of cancer.

Dr. Stephen Grupp on Engineered Cell Therapy for the Treatment of Pediatric ALL

November 5th 2015

Stephen Grupp, MD, PhD, director of translational research for the center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP) and medical director of the Stem Cell Laboratory at CHOP, discusses the use of engineered cell therapy for the treatment of Acute Lymphoblastic Leukemia (ALL).

Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer

November 3rd 2015

Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.

Dr. Richards on Unanswered Questions in Treating Bladder Cancer

November 3rd 2015

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses unanswered questions regarding the treatment of patients with bladder cancer.

Marianne Davies on Managing Immunotherapy Side Effects in Lung Cancer

November 2nd 2015

Marianne Davies, NP, Assistant Professor of and Clinical Instructor in Nursing, Yale Cancer Center, discusses immune-mediated adverse events in lung cancer.

Dr. Minna on Chemotherapy and Radiation Therapy for Lung Cancer

November 2nd 2015

John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

October 30th 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Dr. Yael Cohen on Anti-Angiogenic Agent VB-111

October 29th 2015

Yael Cohen, MD, vice president of Clinical Development at VBL Therapeutics Pharmaceuticals, discusses VB-111, a highly targeted anti-angiogenic agent that is being investigated in several tumor types.

Dr. Vicini on Accelerated Partial Breast Irradiation in Low-Risk Breast Cancer

October 29th 2015

Frank A. Vicini, MD, radiation oncologist, 21st Century Oncology of Michigan, discusses a European study that examined the efficacy of accelerated partial breast irradiation versus conventional whole breast irradiation in patients with low-risk breast cancer.

Dr. Federman on Ongoing Research in Rare Bone and Soft Tissue Sarcoma

October 28th 2015

Noah Federman, MD, director, Pediatric Bone and Soft Tissue Sarcoma Program, University of California, Los Angeles (UCLA), discusses ongoing research in rare bone and soft tissue sarcoma.

Dr. Kipps on Frontline Therapies in CLL

October 27th 2015

Thomas J. Kipps, MD, PhD, deputy director of Research, Moores University of California, San Diego Cancer Center, professor of Medicine, University of California San Diego, School of Medicine, discusses use of frontline therapies for patients with chronic lymphocytic leukemia.